Citace záznamu

Citace podle APA (7th ed.)
Khaled, N. B., Ehmer, U., Kubisch, I., Gonzalez-Carmona, M. A., Philipp, A., Seidensticker, M., . . . Toni, E. N. D. (2026). Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: The MONTBLANC trial protocol (AIO-HEP-0325/ass). SAGE Publishing.
Citace podle Chicago (17th ed.)
Khaled, Najib Ben, et al. Sequential or Upfront Triple Combination with Durvalumab, Tremelimumab, and Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma: The MONTBLANC Trial Protocol (AIO-HEP-0325/ass). SAGE Publishing, 2026.
Citace podle MLA (9th ed.)
Khaled, Najib Ben, et al. Sequential or Upfront Triple Combination with Durvalumab, Tremelimumab, and Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma: The MONTBLANC Trial Protocol (AIO-HEP-0325/ass). SAGE Publishing, 2026.
Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..